Navigation Links
Sihuan's First-to-market Generic Drug Roxatidine Passes On-site Inspection for Drug Registration Conducted by the Chinese State Food and Drug Administration
Date:5/25/2012

HONG KONG, May 25, 2012 /PRNewswire-Asia/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460) ("Sihuan Pharmaceutical" or the "Company"), a leading pharmaceutical company with the largest cardio-cerebral vascular drug franchise ("CCV") in China's prescription market, announced that Roxatidine Acetate Hydrochloride for Injection ("Roxatidine"), Sihuan Pharmaceutical's first-to-market generic drug, recently passed on-site inspection for drug registration conducted by the Chinese State Food and Drug Administration ("SFDA"). Expecting to obtain approval for production in the next three months, the Company plans to launch the drug to the market in the second half of the year, with hospitals as its major target market. It will be manufactured by Beijing Sihuan Pharmaceutical Co., Ltd., a wholly-owned manufacturing subsidiary.

Roxatidine is the fourth generation H2 receptor antagonist. The drug is categorized into two formulations - oral and injectable. The oral form of the drug was first launched in Japan in 1986 and is mainly used for gastric and duodenal ulcers, zollinger-ellison syndrome, reflux esophagitis and gastritis. The injectable form of the drug, which debuted in Japan in, is mainly used for upper gastrointestinal bleeding and pre-anesthesia application. Currently, Roxatidine is widely used in various countries, including Korea, Germany, Italy, the Netherlands, Greece and South Africa.  

Compared with other H2 receptor antagonists, the Roxatidine contains higher selectivity for H2 receptors and features a stronger effect on acid suppression. In addition, it contains a protective mucosal effect that other H2 receptors do not have. Although the Roxatidine has similar therapeutic efficacy to Proton pump inhibitors, it is safer, more stable and more cost-effective. These outstanding advantages are a testament to Roxatidine's clinical value. As a result, Roxatidine has been the first-line drug used for upper gastrointestinal bleeding in the overseas markets.

Gastrointestinal ulcers and bleeding is a common disease in China and has a significant patient base. With the fast-paced living environment, accelerated urbanization and the persistently high stress levels, the incidence rate of such diseases has been increasing each year. Overall incidences of digestive diseases afflict 10% - 20% of the total population and have high recurrence rates. As at the end of 2011, the size of the market has reached RMB$25 billion, bringing promising market potential and prospects.

Dr. Che Fengsheng, Chairman and CEO of Sihuan Pharmaceutical, said, "Capitalising on the characteristics and advantages of Roxatidine, along with Sihuan Pharmaceutical's strong sales and marketing capabilities and nationwide sales network, we believe that this drug will bring its clinical therapeutic value into play with wide clinical use. Building on its leading position in the CCV drug market, Sihuan Pharmaceutical's launch of Roxatidine signifies Sihuan Pharmaceutical's foray into the digestive system therapeutic area. This strategic move is set to further promote the continued development and growth of Sihuan, thereby creating lucrative returns for the Company and its shareholders."

About Sihuan Pharmaceutical Holdings Group Ltd.

Founded in 2001, Sihuan Pharmaceutical Holdings Group Ltd. is a leading pharmaceutical company and the largest cardio-cerebral vascular drug franchise in China's prescription market. The success of the Group can be attributed to its differentiated and proven sales and marketing model, diversified portfolio of market leading drugs, extensive nationwide distribution network and strong research and development capabilities. Its major products such as Kelinao, Anjieli, Chuanqing, Qu'Ao GM1 and Oudimei are widely used in the treatment of various cardio-cerebral vascular diseases.

For further enquiries, please contact Hill+Knowlton Strategies Asia.

Angela Kung
Tel: (852) 2894 6374 / 6017 7030
Email: angela.kung@hkstrategies.com

Ada Ho
Tel: (852) 2894 6290 / 9240 8639
Email: ada.ho@hkstrategies.com


'/>"/>
SOURCE Sihuan Pharmaceutical Holdings Group Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis First-To-Market with Generic Equivalents of Clobex® Shampoo and Clobex® Topical Lotion
2. Bapineuzumab To Become the First-to-Market Disease-Modifying Alzheimers Drug After Flurizans Discontinuation
3. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
4. Mylan Launches Generic Version of Viramune® Tablets
5. Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.
6. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
7. Mylan Launches Generic Version of Plavix® Tablets
8. Mylan Launches Generic Lipitor® in Five European Countries
9. Coloplast Wins Patent Infringement Verdict Against Generic Medical Devices, Inc.
10. Mylan Launches Generic Version of Zyprexa® Tablets
11. Watson Launches Generic FORTAMET(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Jan. 24, 2017   Keneric Healthcare , ... cost effective patient care products, today announced their ... expand the reach of both companies by leveraging ... expertise. Angelini Pharma Inc ... now include Keneric Healthcare,s RTD™ Wound Dressing (antibacterial/antifungal). ...
(Date:1/24/2017)... FRANCISCO , January 24, 2017 The global  ... USD 239.8 billion by 2025, based on a new report by Grand ... cancer is projected to drive the market over the forecast period. Advancements ... are also estimated to boost growth.  Continue ... ...
(Date:1/24/2017)... , Jan. 23, 2017 Optoelectronic ... and control light. The interaction of these components ... in a wide range of applications. These components ... and defense, telecommunications, and healthcare among others. ... owing to its low power consumption, reliability, scalability, ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... ... of a new report from the Frank Hawkins Kenan Institute of Private ... business leaders, academics and policy makers identified concrete solutions at the “What’s Next, ...
(Date:1/24/2017)... , ... January 24, 2017 , ... The NewKILO JRP, ... Institutes (NMIs) and co-funded by the European Union (EU), was completed in May 2015. ... vacuum, instead being maintained and used in air, which presents some challenges to establishing ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... A yellow ... lives in the last month. Yellow fever is primarily spread through contact with infected ... community’s focus on how to prevent its spread. , According to multiple health organizations, ...
(Date:1/24/2017)... ... ... “Who Would Have Dreamed: A Novel of Miracles”: a beautiful and poignant glimpse into ... purpose in her life. “Who Would Have Dreamed: A Novel of Miracles” is the creation ... writing. , Sharon shares that she started her spiritual journey later in life, ...
(Date:1/24/2017)... ... January 24, 2017 , ... HealthCarePoint ... survivors, today announced formation of its first global advisory board to help ... , Like HCP founders, the global advisory board is composed of key ...
Breaking Medicine News(10 mins):